Europe stocks up on Gilead's remdesivir as Covid-19 infections spike

📆 10/8/2020 1:29 PM
📰 The Straits Times

⏱ Reading Time:
19 sec. here
2 min. at publisher
📊 Quality Score:
News: 11%
Publisher: 63%

Business News News

Business Business Latest News,Business Business Headlines

BRUSSELS (REUTERS) - Gilead Sciences said on Thursday (Oct 8) that it had agreed to sell Europe up to 500,0000 courses of its antiviral drug remdesivir, as the continent shores up supplies of one of only two drugs approved to treat Covid-19 patients ahead of the winter.. Read more at straitstimes.com.

BRUSSELS - Gilead Sciences said on Thursday that it had agreed to sell Europe up to 500,0000 courses of its antiviral drug remdesivir, as the continent shores up supplies of one of only two drugs approved to treat Covid-19 patients ahead of the winter.

New cases have been spiralling in Europe as the coming winter drives more people indoors, with cases soaring in neighbouring countries including Belgium, France and the Netherlands. EQUITABLE ACCESS The deal will help ease concerns about availability of the medicine after the company pledged most of its output to its home market over the summer months.

Write Comment

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Europe: Shares edge higher as robust earnings offset US stimulus doubts[BENGALURU] European stocks edged higher on Wednesday as upbeat earnings reports from UK's Tesco and Germany's Dialog Semiconductor helped offset uncertainties surrounding a fresh US stimulus package. Read more at The Business Times.
Source: BusinessTimes - 🏆 15. / 51 Read more »